文献速递肺血管病与心包/心肌炎

靶向VEGF-A/VEGFR2 Y949信号介导的血管通透性可缓解缺氧性肺动脉高压

Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension.
PubMed 文献 · Circulation · 2022-11-17

该研究在肺动脉高压患者和小鼠中探究VEGF-A/VEGFR2 Y949信号的作用,发现缺氧性肺动脉高压存在过度肺血管渗漏且由该信号轴过度激活所致;通过Vefgr2Y949F点突变阻断该信号可减轻肺动脉高压表现,而内皮细胞缺失Vegfr2则促进肺动脉高压。

要点

  • VEGF-A/VEGFR2 Y949信号过度激活导致肺血管渗漏并参与缺氧性肺动脉高压。
  • Vefgr2Y949F点突变阻断该信号可预防血管通透性增加并缓解肺动脉高压。
  • 内皮细胞条件性缺失Vegfr2促进肺动脉高压,提示不能整体阻断VEGFR2。

核心结论

  • VEGF-A/VEGFR2 Y949依赖的血管通透性是肺动脉高压发病的重要决定因素,可能成为有吸引力的治疗靶点。

研究设计与样本

  • 研究检测了肺动脉高压患者肺样本和缺氧小鼠中VEGF-A/VEGFR2信号激活及VEGFR2 Y949依赖的血管渗漏。
  • 使用携带Vegfr2 Y949F点突变(酪氨酸949替换为苯丙氨酸)的突变小鼠及慢性缺氧后内皮细胞条件性缺失Vegfr2的小鼠,评估右心室收缩压、右心室肥厚和肺血管病变。

主要发现

  • 肺动脉高压患者和缺氧小鼠均存在过度肺血管渗漏,由VEGF-A/VEGFR2 Y949信号轴过度激活所致。
  • 缺氧性肺动脉高压中,内皮细胞Yes1和c-Src激活及VE-钙黏蛋白磷酸化参与VEGFR2 Y949诱导的血管通透性。
  • Vefgr2Y949F点突变阻断VEGFR2 Y949信号可预防肺血管通透性增加、抑制巨噬细胞浸润和平滑肌细胞Rac1激活,从而减轻远端肺小动脉肌化、右心室收缩压升高和右心室肥厚。
  • 髓系细胞(包括巨噬细胞)中的VEGFR2 Y949信号对缺氧诱导的血管异常和肺动脉高压微不足道且非必需。
  • 与选择性阻断VEGFR2 Y949信号相反,内皮细胞条件性缺失Vegfr2破坏整个VEGFR2信号会促进肺动脉高压发展。

临床怎么用

  • 选择性靶向VEGF-A/VEGFR2 Y949信号通路可能作为肺动脉高压的治疗策略。
  • 应避免整体阻断内皮细胞VEGFR2信号,因其可能促进肺动脉高压。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) is associated with increased expression of VEGF-A (vascular endothelial growth factor A) and its receptor, VEGFR2 (vascular endothelial growth factor 2), but whether and how activation of VEGF-A signal participates in the pathogenesis of PH is unclear. METHODS: VEGF-A/VEGFR2 signal activation and VEGFR2 Y949-dependent vascular leak were investigated in lung samples from patients with PH and mice exposed to hypoxia. To study their mechanistic roles in hypoxic PH, we examined right ventricle systolic pressure, right ventricular hypertrophy, and pulmonary vasculopathy in mutant mice carrying knock-in of phenylalanine that replaced the tyrosine at residual 949 of VEGFR2 (Vefgr2Y949F) and mice with conditional endothelial deletion of Vegfr2 after chronic hypoxia exposure. RESULTS: We show that PH leads to excessive pulmonary vascular leak in both patients and hypoxic mice, and this is because of an overactivated VEGF-A/VEGFR2 Y949 signaling axis. In the context of hypoxic PH, activation of Yes1 and c-Src and subsequent VE-cadherin phosphorylation in endothelial cells are involved in VEGFR2 Y949-induced vascular permeability. Abolishing VEGFR2 Y949 signaling by Vefgr2Y949F point mutation was sufficient to prevent pulmonary vascular permeability and inhibit macrophage infiltration and Rac1 activation in smooth muscle cells under hypoxia exposure, thereby leading to alleviated PH manifestations, including muscularization of distal pulmonary arterioles, elevated right ventricle systolic pressure, and right ventricular hypertrophy. It is important that we found that VEGFR2 Y949 signaling in myeloid cells including macrophages was trivial and dispensable for hypoxia-induced vascular abnormalities and PH. In contrast with selective blockage of VEGFR2 Y949 signaling, disruption of the entire VEGFR2 signaling by conditional endothelial deletion of Vegfr2 promotes the development of PH. CONCLUSIONS: Our results support the notion that VEGF-A/VEGFR2 Y949-dependent vascular permeability is an important determinant in the pathogenesis of PH and might serve as an attractive therapeutic target pathway for this disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zhou W, Liu K, Zeng L, et al. Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension. Circulation. 2022. PMID: 36384284. doi:10.1161/CIRCULATIONAHA.122.061900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。